A Case of Metastatic Adamantinoma ThatResponded Well to Sunitinib

Adamantinoma is a rare low-grade malignant bone tumor of epithelial origin. Metastatic adamantinoma has been reported to beresistant to chemotherapy. We report a case of metastatic adamantinoma to the lung, 10 years after the initial diagnosis of tibialmass. The patient received radiation therapy to the lung with partial response. A surveillance PET scan revealed progression of thelung mass and biopsy confirmed to be progressive residual metastatic adamantinoma. He received carboplatin and etoposide for 7months and achieved a partial response. Four months later, PET scan showed disease progression. We started him on sunitinib, amultikinase inhibitor. He achieved a good partial response for 3 years. He died due to pneumonia at the age of 72